Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEALAC-01
2025-524862-12-00Phase 4Authorised
- Sponsor
- Université libre de Bruxelles
- Start
- Apr 2026
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of M-M-R II in measles, mumps and rubella (2 arms), sponsored by Université libre de Bruxelles. Planned start Apr 2026; status: authorised.
02
Drugs
M-M-R II
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on 2025-524862-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524862-12-00.